{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T17:45:39Z","timestamp":1772646339036,"version":"3.50.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s40262-025-01598-x","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T14:41:54Z","timestamp":1767624114000},"page":"417-429","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Population Pharmacokinetic and Pharmacodynamic Modeling to Support Molar Dose Ratio Determination of Long-Acting Insulin Analogs"],"prefix":"10.1007","volume":"65","author":[{"given":"Dan","family":"Tang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuehu","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang","family":"Shu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanli","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoling","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daren","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0439-635X","authenticated-orcid":false,"given":"Sheng","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,5]]},"reference":[{"issue":"Suppl 1","key":"1598_CR1","doi-asserted-by":"publisher","first-page":"S81","DOI":"10.2337\/dc14-S081","volume":"37","author":"American Diabetes Association","year":"2014","unstructured":"American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014;37(Suppl 1):S81-90.","journal-title":"Diabetes Care"},{"issue":"Supplement_1","key":"1598_CR2","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.2337\/dc25-S002","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","unstructured":"American Diabetes Association Professional Practice Committee. Diagnosis and classification of diabetes: standards of care in diabetes-2025. Diabetes Care. 2025;48(Supplement_1):S27\u201349.","journal-title":"Diabetes Care"},{"issue":"2","key":"1598_CR3","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1002\/dmrr.2469","volume":"30","author":"DR Owens","year":"2014","unstructured":"Owens DR, Matfin G, Monnier L. Basal insulin analogues in the management of diabetes mellitus: what progress have we made? Diabetes Metab Res Rev. 2014;30(2):104\u201319.","journal-title":"Diabetes Metab Res Rev"},{"issue":"10","key":"1598_CR4","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1111\/j.1463-1326.2012.01638.x","volume":"14","author":"T Heise","year":"2012","unstructured":"Heise T, Nosek L, B\u00f8ttcher SG, Hastrup H, Haahr H. Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes. Diabetes Obes Metab. 2012;14(10):944\u201350.","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"1598_CR5","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1111\/dom.12052","volume":"15","author":"SC Gough","year":"2013","unstructured":"Gough SC, Harris S, Woo V, Davies M. Insulin degludec: overview of a novel ultra long-acting basal insulin. Diabetes Obes Metab. 2013;15(4):301\u20139.","journal-title":"Diabetes Obes Metab"},{"key":"1598_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1294810","volume":"14","author":"KG Chen","year":"2023","unstructured":"Chen KG, Zhang YH, Ye PP, et al. Pharmacokinetics and bioavailability of a new long-acting insulin analog in healthy Chinese volunteers: an open, randomized, single-dose, two-period and two-sequence cross-over study. Front Pharmacol. 2023;14:1294810.","journal-title":"Front Pharmacol"},{"issue":"1","key":"1598_CR7","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1177\/1932296817707542","volume":"12","author":"Y Qu","year":"2018","unstructured":"Qu Y, Luo J, Garhyan P, Antalis CJ, Chang AM, Jacober SJ. Dose unit establishment for a new basal insulin using joint modeling of insulin dose and glycemic response. J Diabetes Sci Technol. 2018;12(1):155\u201362.","journal-title":"J Diabetes Sci Technol"},{"issue":"3","key":"1598_CR8","first-page":"E214","volume":"237","author":"RA DeFronzo","year":"1979","unstructured":"DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 1979;237(3):E214\u201323.","journal-title":"Am J Physiol"},{"issue":"5","key":"1598_CR9","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1089\/dia.2004.6.698","volume":"6","author":"L Heinemann","year":"2004","unstructured":"Heinemann L, Anderson JH Jr. Measurement of insulin absorption and insulin action. Diabetes Technol Ther. 2004;6(5):698\u2013718.","journal-title":"Diabetes Technol Ther"},{"issue":"10","key":"1598_CR10","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1111\/dom.12703","volume":"18","author":"T Heise","year":"2016","unstructured":"Heise T, Zijlstra E, Nosek L, Heckermann S, Plum-M\u00f6rschel L, Forst T. Euglycaemic glucose clamp: what it can and cannot do, and how to do it. Diabetes Obes Metab. 2016;18(10):962\u201372.","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"1598_CR11","doi-asserted-by":"publisher","first-page":"418","DOI":"10.2133\/dmpk.DMPK-10-RG-017","volume":"25","author":"CB Landersdorfer","year":"2010","unstructured":"Landersdorfer CB, Jusko WJ. Pharmacokinetic\/pharmacodynamic modeling of glucose clamp effects of inhaled and subcutaneous insulin in healthy volunteers and diabetic patients. Drug Metab Pharmacokinet. 2010;25(5):418\u201329.","journal-title":"Drug Metab Pharmacokinet"},{"issue":"6","key":"1598_CR12","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1002\/psp4.12189","volume":"6","author":"D R\u00fcppel","year":"2017","unstructured":"R\u00fcppel D, Dahmen R, Boss A, J\u00e4ger R, Grant M, Baughman R, et al. A population dose-response model for inhaled technosphere insulin administered to healthy subjects. CPT Pharmacometrics Syst Pharmacol. 2017;6(6):365\u201372.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"1","key":"1598_CR13","doi-asserted-by":"publisher","first-page":"64","DOI":"10.2337\/diacare.17.1.64","volume":"17","author":"JR Woodworth","year":"1994","unstructured":"Woodworth JR, Howey DC, Bowsher RR. Establishment of time-action profiles for regular and NPH insulin using pharmacodynamic modeling. Diabetes Care. 1994;17(1):64\u20139.","journal-title":"Diabetes Care"},{"issue":"4","key":"1598_CR14","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1177\/1932296814532326","volume":"8","author":"A de la Pe\u00f1a","year":"2014","unstructured":"de la Pe\u00f1a A, Ma X, Reddy S, Ovalle F, Bergenstal RM, Jackson JA. Application of PK\/PD modeling and simulation to dosing regimen optimization of high-dose human regular U-500 insulin. J Diabetes Sci Technol. 2014;8(4):821\u20139.","journal-title":"J Diabetes Sci Technol"},{"issue":"5","key":"1598_CR15","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1111\/bcp.13180","volume":"83","author":"W de Winter","year":"2017","unstructured":"de Winter W, Dunne A, de Trixhe XW, et al. Dynamic population pharmacokinetic\u2013pharmacodynamic modelling and simulation supports similar efficacy in glycosylated haemoglobin response with once or twice\u2010daily dosing of canagliflozin. Br J Clin Pharmacol. 2017;83(5):1072\u201381.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"1598_CR16","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","volume":"13","author":"M Bergstrand","year":"2011","unstructured":"Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011;13(2):143\u201351.","journal-title":"AAPS J"},{"key":"1598_CR17","unstructured":"Insulin Degludec. Clinical pharmacology and biopharmaceutics review: NDA 203313. Silver Spring: U.S. Food and Drug Administration; 2015. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2015\/203313Orig1s000_203314Orig1s000ClinPharmR.pdf."},{"issue":"12","key":"1598_CR18","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1002\/cpdd.1152","volume":"11","author":"AV Petrov","year":"2022","unstructured":"Petrov AV, Zinnatulina BR, Drai RV, et al. PKPD modeling and simulations to support biosimilar development of biphasic insulin aspart 30. Clin Pharmacol Drug Dev. 2022;11(12):1457\u201366.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"9","key":"1598_CR19","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.2337\/dc06-1120","volume":"29","author":"ZT Bloomgarden","year":"2006","unstructured":"Bloomgarden ZT, Dodis R, Viscoli CM, Holmboe ES, Inzucchi SE. Lower baseline glycemia reduces apparent oral agent glucose-lowering efficacy: a meta-regression analysis. Diabetes Care. 2006;29(9):2137\u20139.","journal-title":"Diabetes Care"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01598-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-025-01598-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01598-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T14:38:20Z","timestamp":1772635100000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-025-01598-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,5]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["1598"],"URL":"https:\/\/doi.org\/10.1007\/s40262-025-01598-x","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,5]]},"assertion":[{"value":"13 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors are employees of Jiangsu Hengrui Pharmaceuticals and have no conflicts to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All studies included in this analysis were approved by appropriate ethics committees and were conducted in accordance with the principles of the Declaration of Helsinki and the International Council for Harmonisation Good Clinical Practice guidelines.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all participants prior to study inclusion.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The data that support the findings of this study are not openly available owing to reasons of sensitivity but are available from the corresponding author upon reasonable request.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not available.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"D.T. analyzed the data and drafted the manuscript. X.G., X.Y., and H.C. designed and performed the research. X.L., X.Z., and D.C. collated the dataset. M.Z., Y.D., and C.S. reviewed the manuscript, S.F. critically revised the manuscript for important intellectual content. All authors read and approved the final manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}